Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May;173(3):444-55.
doi: 10.1111/bjh.13977. Epub 2016 Mar 7.

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

Rohtesh S Mehta  1 , Rima M Saliba  1 , Julianne Chen  1 , Gabriela Rondon  1 , Aimee E Hammerstrom  1 , Amin Alousi  1 , Muzaffar Qazilbash  1 , Qaiser Bashir  1 , Sairah Ahmed  1 , Uday Popat  1 , Chitra Hosing  1 , Issa Khouri  1 , Elizabeth J Shpall  1 , Richard E Champlin  1 , Stefan O Ciurea  1
Affiliations

Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation

Rohtesh S Mehta et al. Br J Haematol. 2016 May.

Abstract

Post-transplantation cyclophosphamide (PTCy) is an effective strategy to prevent graft-versus-host disease (GVHD) after haploidentical haematopoietic cell transplantation (HCT). We determined the efficacy of PTCy-based GVHD prophylaxis in human leucocyte antigen (HLA)-mismatched unrelated donor (MMUD) HCT. We analysed 113 adult patients with high-risk haematological malignancies who underwent one-antigen MMUD transplantation between 2009 and 2013. Of these, 41 patients received PTCy, tacrolimus and mycophenolate mofetil (MMF) for GVHD prophylaxis; 72 patients received conventional prophylaxis with anti-thymocyte globulin, tacrolimus and methotrexate. Graft source was primarily bone marrow (83% PTCy vs. 63% conventional group). Incidence of grade II-IV (37% vs. 36%, P = 0·8) and grade III-IV (17% vs. 12%, P = 0·5) acute GVHD was similar at day 100. However, the incidence of grade II-IV acute GVHD by day 30 was significantly lower in the PTCy group (0% vs. 15%, P = 0·01). Median time to neutrophil (18 days vs. 12 days, P < 0·001) and platelet (25·5 days vs. 18 days, P = 0·05) engraftment was prolonged in PTCy group. Rates of graft failure, chronic GVHD, 2-year non-relapse mortality, relapse, progression-free survival or overall survival were similar. Our results demonstrate that PTCy, tacrolimus and MMF for GVHD prophylaxis is safe and produced similar results as conventional prophylaxis in patients with one antigen HLA-MMUD HCT.

Keywords: GVHD; HLA-mismatched transplantation; MMUD; post transplantation cyclophosphamide; unrelated donor.

PubMed Disclaimer

Conflict of interest statement

Disclosure of conflicts of interest

The authors do not have any conflicts of interest.

Figures

Fig 1
Fig 1
Cumulative incidence of grade II–IV and III–IV acute graft-versus-host disease (aGVHD) by day 100 in the post-transplant cyclophosphamide (PTCy) group (solid line) compared with the conventional group (dotted line), all patients.
Fig 2
Fig 2
(A) Cumulative incidence of non-relapse mortality (NRM), (B) progression-free survival and (C) overall survival in the post-transplant cyclophosphamide (PTCy) group compared with the conventional group, all patients.
See this image and copyright information in PMC

References

    1. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biology of Blood and Marrow Transplantation. 2011;17:1490–1496. - PMC - PubMed
    1. Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kroger N, Zander AR. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Experimental Hematology. 2008;36:1047–1054. - PubMed
    1. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO) Blood. 2001;98:2942–2947. - PubMed
    1. Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Grasso R, Pozzi S, Colombo N, Tedone E, Varaldo R, Raiola AM. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transplantation. 2015;50:S37–S39. - PubMed
    1. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H, Handgretinger R, Einsele H, Niemeyer C, Benda N, Faul C, Kanz L, Niethammer D, Klingebiel T. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplantation. 1998;21:487–495. - PubMed